APDC ADVANCED PHARMACEUTICAL DEVELOPMENT CENTER Trademark

Trademark Overview

On Monday, December 19, 2022, a trademark application was filed for APDC ADVANCED PHARMACEUTICAL DEVELOPMENT CENTER with the United States Patent and Trademark Office. The USPTO has given the APDC ADVANCED PHARMACEUTICAL DEVELOPMENT CENTER trademark a serial number of 97723397. The federal status of this trademark filing is STATEMENT OF USE - TO EXAMINER as of Wednesday, September 18, 2024. This trademark is owned by Phlow Corp.. The APDC ADVANCED PHARMACEUTICAL DEVELOPMENT CENTER trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical research and development

General Information

Serial Number97723397
Word MarkAPDC ADVANCED PHARMACEUTICAL DEVELOPMENT CENTER
Filing DateMonday, December 19, 2022
Status748 - STATEMENT OF USE - TO EXAMINER
Status DateWednesday, September 18, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 16, 2023

Trademark Statements

NOT AVAILABLE"ADVANCED PHARMACEUTICAL DEVELOPMENT CENTER"
Goods and ServicesPharmaceutical research and development

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateSunday, January 15, 2023
Primary Code042
First Use Anywhere DateTuesday, September 13, 2022
First Use In Commerce DateMonday, December 12, 2022

Trademark Owner History

Party NamePhlow Corp.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressRichmond, VA 23219
Party NamePhlow Corp.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressRichmond, VA 23219

Trademark Events

Event DateEvent Description
Thursday, December 22, 2022NEW APPLICATION ENTERED
Sunday, January 15, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, March 28, 2023ASSIGNED TO EXAMINER
Friday, March 31, 2023NON-FINAL ACTION WRITTEN
Friday, March 31, 2023NON-FINAL ACTION E-MAILED
Friday, March 31, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, April 5, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, April 5, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, April 6, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, April 7, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 26, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 16, 2023PUBLISHED FOR OPPOSITION
Tuesday, May 16, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 11, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, December 13, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 18, 2024SOU TEAS EXTENSION RECEIVED
Monday, December 11, 2023SOU TEAS EXTENSION RECEIVED
Monday, December 11, 2023SOU EXTENSION 1 FILED
Monday, December 11, 2023SOU EXTENSION 1 GRANTED
Tuesday, June 18, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 18, 2024SOU EXTENSION 2 GRANTED
Tuesday, July 16, 2024USE AMENDMENT FILED
Tuesday, July 16, 2024TEAS STATEMENT OF USE RECEIVED
Wednesday, September 18, 2024STATEMENT OF USE PROCESSING COMPLETE
Wednesday, September 18, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, June 18, 2024SOU EXTENSION 2 FILED

Related Keywords

center development pharmaceutical advanced apdc research